High-Dose of oral Montelukast Induces Monoamines Depletion and brain-Derived Neurotrophic Factor BDNF Upregulation in male Rat's Brain
DOI:
https://doi.org/10.32947/ajps.v26i1.1349Keywords:
Montelukast, Reserpine, BDNF, Serotonin, DopamineAbstract
Background: Montelukast, a leukotriene D4 antagonist used for asthma and allergic rhinitis, has been increasingly linked to neuropsychiatric effects, including mood disorders and suicidality. Its impact on central monoamine neurotransmitters and neurotrophic factors remains unclear.
Objective: This study aimed to evaluate the impact of montelukast on monoamine neurotransmitters and brain-derived neurotrophic factor (BDNF) in rats, in conjunction with a histological analysis of brain tissue.
Methods: Thirty-five male albino rats were randomly assigned to five groups (n=7 each): a negative control, a positive control given reserpine (0.2 mg/kg, i.p.), and three groups receiving oral montelukast at 5, 10, and 20 mg/kg/day for 14 days. Monoamines (dopamine, serotonin, norepinephrine) and BDNF were measured using ELISA. Histopathological changes were examined with H&E staining.
Results: Montelukast treatment resulted in a dose-dependent decrease in dopamine, serotonin, and norepinephrine, akin to the monoamine depletion caused by reserpine. Notably, BDNF levels were markedly increased in both the reserpine group and the high-dose montelukast group (20 mg/kg). Histological analysis demonstrated normal neuronal morphology at low dose, but higher doses (10 and 20 mg/kg/day) resulted in moderate vascular congestion and neuronal edema without necrosis.
Conclusion: Montelukast causes considerable monoamine depletion and a counterintuitive increase in BDNF at elevated dosages, with initial neurotoxic histopathological alterations in the brain tissues of male rats. Further detailed studies are warranted to determine whether these modifications contribute to the neuropsychiatric side effects observed in clinical environments.
References
1- Cognitive Effects of Montelukast: A Pharmaco-EEG Study - PMC [Internet]. [cited 2025 Nov 16]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8145277/
2- Sood R, Anoopkumar-Dukie S, Rudrawar S, Hall S. Neuromodulatory effects of leukotriene receptor antagonists: A comprehensive review. Eur J Pharmacol. 2024 Sept 5; 978:176755.
3- Mahdi MR, Abbas WAK, Jasim GA. Histopathological evaluation of induced pulmonary fibrosis under the effect of montelukast. Al Mustansiriyah J Pharm Sci. 2023 Feb 28;23(1):14–21.
4- Datusalia AK, Singh G, Yadav N, Gaun S, Manik M, Singh RK. Targeted Delivery of Montelukast for the Treatment of Alzheimer’s Disease. CNS Neurol Disord Drug Targets. 2022;21(10):913–25.
5- Ahmed BM, Mansour NO, Sallam RA, Soliman MM. Efficacy of montelukast as an adjuvant therapy in rheumatoid arthritis patients: A randomized controlled study. Int Immunopharmacol. 2023 Nov;124(Pt B):110959.
6- Research C for DE and. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. FDA [Internet]. 2025 Feb 20 [cited 2025 July 30]; Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug
7- Marques CF, Marques MM, Justino GC. The mechanisms underlying montelukast’s neuropsychiatric effects - new insights from a combined metabolic and multiomics approach. Life Sci. 2022 Dec 1; 310:121056.
8- Jiang Y, Zou D, Li Y, Gu S, Dong J, Ma X, et al. Monoamine Neurotransmitters Control Basic Emotions and Affect Major Depressive Disorders. Pharmaceuticals. 2022 Oct;15(10):1203.
9- Monoamine Neurotransmitters Control Basic Emotions and Affect Major Depressive Disorders - PMC [Internet]. [cited 2026 Jan 9]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9611768/
10- Antkiewicz-Michaluk L, Wąsik A, Możdżeń E, Romańska I, Michaluk J. Antidepressant-like Effect of Tetrahydroisoquinoline Amines in the Animal Model of Depressive Disorder Induced by Repeated Administration of a Low Dose of Reserpine: Behavioral and Neurochemical Studies in the Rat. Neurotox Res. 2014;26(1):85–98.
11- Tel BC, Telli G, Onder S, Nemutlu E, Bozkurt TE. Investigation of the relationship between chronic montelukast treatment, asthma and depression‑like behavior in mice. Exp Ther Med. 2021 Jan 1;21(1):1–1.
12- Ahmed SM, Kamal YM, Waheed HJ, Alqallaf SM. Amelioration of Chlorpromazine-Induced Sexual Dysfunction in Male Rats by Mucuna Pruriens Seeds Extract. Al Mustansiriyah J Pharm Sci. 2025 Aug 31;25(3):327–39.
13- Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016 Mar;7(2):27–31.
14- Blood–Brain Barrier Leakage during Early Epileptogenesis Is Associated with Rapid Remodeling of the Neurovascular Unit | eNeuro [Internet]. [cited 2026 Jan 9]. Available from: https://www.eneuro.org/content/5/3/ENEURO.0123-18.2018.short
15- Liu HN, Nakamura M, Kawashima H. New Role of the Serotonin as a Biomarker of Gut–Brain Interaction. Life [Internet]. 2024 Oct 9 [cited 2026 Jan 11];14(10). Available from: https://www.mdpi.com/2075-1729/14/10/1280
16- Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol. 2007 Sept;18(5–6):391.
17- Koyya P, Manthari RK, Pandrangi SL. Brain-Derived Neurotrophic Factor - The Protective Agent Against Neurological Disorders. CNS Neurol Disord Drug Targets. 2024;23(3):353–66.
18- Arévalo JC, Deogracias R. Mechanisms Controlling the Expression and Secretion of BDNF. Biomolecules. 2023 May 2;13(5):789.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Karar Haider Fadhel, Yassir Mustafa Kamal Al Mulla Hummadi, Sadeq S. Mahdi Alawi, Mutaz Sabah Ahmeid
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
